A recent investigation suggested that the α7nAChRs exert anti-inflammatory effects via activating adenylyl cyclase-6 and promoting endocytosis of TLR4 mediated by a lipid raft in a COPD mouse model and indicated that the α7nAChR agonists may have the potential to become a novel therapeutic approach for COPD and possibly other inflammatory diseases [84]. The gene discussed is ADCY6; the disease is chronic obstructive pulmonary disease.